All-or-Nothing Biotech Bets Dented by Rising Treasury Yields

Investors are beginning to turn cautious on biotechnology stocks as a rapid rise in Treasury yields dents the appeal for shares of companies that are often viewed as risky all-or-nothing bets on breakthrough medical treatments.

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.